Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Mar;79(9-10):1564–1571. doi: 10.1038/sj.bjc.6690249

Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women

R L Balleine 1, M J Earl 2, M L Greenberg 2,1, C L Clarke 1
PMCID: PMC2362699  PMID: 10188907

Abstract

The relationship between expression of receptors for oestrogen and progesterone (ER and PR) and disease progression in breast cancer was investigated by comparing immunocytochemical determinations of ER and PR in fine needle aspirates from primary and secondary breast tumours. Rates of receptor expression were significantly higher in primary than in secondary lesions: for ER 63.3% (n = 689) compared with 45.3% (n = 223), and for PR 53.7% (n = 443) compared with 33.1% (n = 121). The effect of menopausal status was examined by subdividing the patient cohort into those over or under the age of 50 years. In both instances, ER expression in secondary tumours was relatively low; however, only postmenopausal patients had significantly lower rates of PR expression in secondary tumours. Consistent with this, an increase in the ER+PR– profile in secondary tumours compared with primary cases from postmenopausal patients was seen, and in a multivariate analysis, a specific absence of PR expression in secondary tumours was revealed. Comparison of ER and PR expression in simultaneously sampled primary tumours and lymph node metastases from the same patient showed that receptor expression was stable with progression to a metastatic site as results were concordant for ER in 92% (n = 88) and PR in 93.8% of cases (n = 65). These results suggest that absence of PR expression in primary breast cancer is associated with disease progression and may be a marker of an aggressive tumour phenotype. © 1999 Cancer Research Campaign

Keywords: breast cancer, metastatic, receptors -oestrogen -progesterone

Full Text

The Full Text of this article is available as a PDF (233.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alanko A. Variation of estrogen and progesterone receptor status in breast cancer. Ann Clin Res. 1985;17(1):10–14. [PubMed] [Google Scholar]
  2. Allegra J. C., Barlock A., Huff K. K., Lippman M. E. Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer. 1980 Feb 15;45(4):792–794. doi: 10.1002/1097-0142(19800215)45:4<792::aid-cncr2820450430>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  3. Bonnier P., Romain S., Charpin C., Lejeune C., Tubiana N., Martin P. M., Piana L. Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer. 1995 Jul 17;62(2):138–144. doi: 10.1002/ijc.2910620205. [DOI] [PubMed] [Google Scholar]
  4. Butler J. A., Trezona T., Vargas H., State D. Value of measuring hormone receptor levels of regional metastatic carcinoma of the breast. Arch Surg. 1989 Oct;124(10):1131–1135. doi: 10.1001/archsurg.1989.01410100029006. [DOI] [PubMed] [Google Scholar]
  5. Carter S. L., Negrini M., Baffa R., Gillum D. R., Rosenberg A. L., Schwartz G. F., Croce C. M. Loss of heterozygosity at 11q22-q23 in breast cancer. Cancer Res. 1994 Dec 1;54(23):6270–6274. [PubMed] [Google Scholar]
  6. Chalbos D., Galtier F. Differential effect of forms A and B of human progesterone receptor on estradiol-dependent transcription. J Biol Chem. 1994 Sep 16;269(37):23007–23012. [PubMed] [Google Scholar]
  7. Clark G. M., McGuire W. L., Hubay C. A., Pearson O. H., Marshall J. S. Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med. 1983 Dec 1;309(22):1343–1347. doi: 10.1056/nejm198312013092240. [DOI] [PubMed] [Google Scholar]
  8. Clark G. M., Osborne C. K., McGuire W. L. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 1984 Oct;2(10):1102–1109. doi: 10.1200/JCO.1984.2.10.1102. [DOI] [PubMed] [Google Scholar]
  9. Clarke C. L., Sutherland R. L. Progestin regulation of cellular proliferation. Endocr Rev. 1990 May;11(2):266–301. doi: 10.1210/edrv-11-2-266. [DOI] [PubMed] [Google Scholar]
  10. Crawford D. J., Cowan S., Fitch R., Smith D. C., Leake R. E. Stability of oestrogen receptor status in sequential biopsies from patients with breast cancer. Br J Cancer. 1987 Aug;56(2):137–140. doi: 10.1038/bjc.1987.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Encarnación C. A., Ciocca D. R., McGuire W. L., Clark G. M., Fuqua S. A., Osborne C. K. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat. 1993;26(3):237–246. doi: 10.1007/BF00665801. [DOI] [PubMed] [Google Scholar]
  12. Graham J. D., Clarke C. L. Physiological action of progesterone in target tissues. Endocr Rev. 1997 Aug;18(4):502–519. doi: 10.1210/edrv.18.4.0308. [DOI] [PubMed] [Google Scholar]
  13. Greenberg M. L., Earl M. J., Bilous A. M., Ekberg H., Milliken J., Pacey N. F. Estrogen receptor immunocytochemical assay on cytologic material from primary and metastatic breast cancer. Pathology. 1989 Apr;21(2):93–99. doi: 10.3109/00313028909059543. [DOI] [PubMed] [Google Scholar]
  14. Gross G. E., Clark G. M., Chamness G. C., McGuire W. L. Multiple progesterone receptor assays in human breast cancer. Cancer Res. 1984 Feb;44(2):836–840. [PubMed] [Google Scholar]
  15. Hampton G. M., Mannermaa A., Winqvist R., Alavaikko M., Blanco G., Taskinen P. J., Kiviniemi H., Newsham I., Cavenee W. K., Evans G. A. Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res. 1994 Sep 1;54(17):4586–4589. [PubMed] [Google Scholar]
  16. Harland R. N., Barnes D. M., Howell A., Ribeiro G. G., Taylor J., Sellwood R. A. Variation of receptor status in cancer of the breast. Br J Cancer. 1983 Apr;47(4):511–515. doi: 10.1038/bjc.1983.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hoehn J. L., Plotka E. D., Dickson K. B. Comparison of estrogen receptor levels in primary and regional metastatic carcinoma of the breast. Ann Surg. 1979 Jul;190(1):69–71. doi: 10.1097/00000658-197907000-00015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Horwitz K. B. Is a functional estrogen receptor always required for progesterone receptor induction in breast cancer? J Steroid Biochem. 1981 Dec;15:209–217. doi: 10.1016/0022-4731(81)90277-6. [DOI] [PubMed] [Google Scholar]
  19. Horwitz K. B., McGuire W. L. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem. 1978 Apr 10;253(7):2223–2228. [PubMed] [Google Scholar]
  20. Horwitz K. B., McGuire W. L. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science. 1975 Aug 29;189(4204):726–727. doi: 10.1126/science.168640. [DOI] [PubMed] [Google Scholar]
  21. Hull D. F., 3rd, Clark G. M., Osborne C. K., Chamness G. C., Knight W. A., 3rd, McGuire W. L. Multiple estrogen receptor assays in human breast cancer. Cancer Res. 1983 Jan;43(1):413–416. [PubMed] [Google Scholar]
  22. Hähnel R., Twaddle E. The relationship between estrogen receptors in primary and secondary breast carcinomas and in sequential primary breast carcinomas. Breast Cancer Res Treat. 1985;5(2):155–163. doi: 10.1007/BF01805989. [DOI] [PubMed] [Google Scholar]
  23. Jakesz R., Dittrich C., Hanusch J., Kolb R., Lenzhofer R., Moser K., Rainer H., Reiner G., Schemper M., Spona J. Simultaneous and sequential determinations of steroid hormone receptors in human breast cancer. Influence of intervening therapy. Ann Surg. 1985 Mar;201(3):305–310. doi: 10.1097/00000658-198503000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Johnston S. R., Saccani-Jotti G., Smith I. E., Salter J., Newby J., Coppen M., Ebbs S. R., Dowsett M. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res. 1995 Aug 1;55(15):3331–3338. [PubMed] [Google Scholar]
  25. Kamby C., Rasmussen B. B., Kristensen B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer. 1989 Aug;60(2):252–257. doi: 10.1038/bjc.1989.264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Kraus W. L., Weis K. E., Katzenellenbogen B. S. Determinants for the repression of estrogen receptor transcriptional activity by ligand-occupied progestin receptors. J Steroid Biochem Mol Biol. 1997 Nov-Dec;63(4-6):175–188. doi: 10.1016/s0960-0760(97)00089-7. [DOI] [PubMed] [Google Scholar]
  27. Kraus W. L., Weis K. E., Katzenellenbogen B. S. Inhibitory cross-talk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors. Mol Cell Biol. 1995 Apr;15(4):1847–1857. doi: 10.1128/mcb.15.4.1847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kuukasjärvi T., Kononen J., Helin H., Holli K., Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996 Sep;14(9):2584–2589. doi: 10.1200/JCO.1996.14.9.2584. [DOI] [PubMed] [Google Scholar]
  29. Mattei M. G., Krust A., Stropp U., Mattei J. F., Chambon P. Assignment of the human progesterone receptor to the q22 band of chromosome 11. Hum Genet. 1988 Jan;78(1):96–97. doi: 10.1007/BF00291245. [DOI] [PubMed] [Google Scholar]
  30. McDonnell D. P., Goldman M. E. RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. J Biol Chem. 1994 Apr 22;269(16):11945–11949. [PubMed] [Google Scholar]
  31. McGuire W. L., Chamness G. C., Fuqua S. A. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol. 1991 Nov;5(11):1571–1577. doi: 10.1210/mend-5-11-1571. [DOI] [PubMed] [Google Scholar]
  32. Müller-Holzner E., Zeimet A. G., Daxenbichler G., Marth C., Müller L. C., Dapunt O. Progesterone receptors in routinely paraffin-embedded primary breast carcinomas and lymph node metastases. Breast Cancer Res Treat. 1993;25(1):47–55. doi: 10.1007/BF00662400. [DOI] [PubMed] [Google Scholar]
  33. Nomura Y., Tashiro H., Shinozuka K. Changes of steroid hormone receptor content by chemotherapy and/or endocrine therapy in advanced breast cancer. Cancer. 1985 Feb 1;55(3):546–551. doi: 10.1002/1097-0142(19850201)55:3<546::aid-cncr2820550313>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  34. Osborne C. K., Yochmowitz M. G., Knight W. A., 3rd, McGuire W. L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2884–2888. doi: 10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  35. Paridaens R., Sylvester R. J., Ferrazzi E., Legros N., Leclercq G., Heuson J. C. Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2889–2895. doi: 10.1002/1097-0142(19801215)46:12+<2889::aid-cncr2820461430>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  36. Peetz M. E., Nunley D. L., Moseley H. S., Keenan E. J., Davenport C. E., Fletcher W. S. Multiple simultaneous and sequential estrogen receptor values in patients with breast cancer. Am J Surg. 1982 May;143(5):591–594. doi: 10.1016/0002-9610(82)90170-2. [DOI] [PubMed] [Google Scholar]
  37. Pichon M. F., Broet P., Magdelenat H., Delarue J. C., Spyratos F., Basuyau J. P., Saez S., Rallet A., Courriere P., Millon R. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer. 1996 Jun;73(12):1545–1551. doi: 10.1038/bjc.1996.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Raemaekers J. M., Beex L. V., Koenders A. J., Pieters G. F., Smals A. G., Benraad T. J., Kloppenborg P. W. Concordance and discordance of estrogen and progesterone receptor content in sequential biopsies of patients with advanced breast cancer: relation to survival. Eur J Cancer Clin Oncol. 1984 Aug;20(8):1011–1018. doi: 10.1016/0277-5379(84)90102-0. [DOI] [PubMed] [Google Scholar]
  39. Romain S., Lainé Bidron C., Martin P. M., Magdelenat H. Steroid receptor distribution in 47,892 breast cancers. A collaborative study of 7 European laboratories. The EORTC Receptor Study Group. Eur J Cancer. 1995;31A(3):411–417. doi: 10.1016/0959-8049(94)00496-r. [DOI] [PubMed] [Google Scholar]
  40. Saez S., Martin P. M., Chouvet C. D. Estradiol and progesterone receptor levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels. Cancer Res. 1978 Oct;38(10):3468–3473. [PubMed] [Google Scholar]
  41. Spataro V., Price K., Goldhirsch A., Cavalli F., Simoncini E., Castiglione M., Rudenstam C. M., Collins J., Lindtner J., Gelber R. D. Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol. 1992 Nov;3(9):733–740. doi: 10.1093/oxfordjournals.annonc.a058330. [DOI] [PubMed] [Google Scholar]
  42. Thorpe S. M. Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance. Acta Oncol. 1988;27(1):1–19. doi: 10.3109/02841868809090312. [DOI] [PubMed] [Google Scholar]
  43. Thorpe S. M., Rose C. Oestrogen and progesterone receptor determinations in breast cancer: technology and biology. Cancer Surv. 1986;5(3):505–525. [PubMed] [Google Scholar]
  44. Tomlinson I. P., Nicolai H., Solomon E., Bodmer W. F. The frequency and mechanism of loss of heterozygosity on chromosome 11q in breast cancer. J Pathol. 1996 Sep;180(1):38–43. doi: 10.1002/(SICI)1096-9896(199609)180:1<38::AID-PATH638>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  45. Webster D. J., Bronn D. G., Minton J. P. Estrogen receptor levels in multiple biopsies from patients with breast cancer. Am J Surg. 1978 Sep;136(3):337–338. doi: 10.1016/0002-9610(78)90289-1. [DOI] [PubMed] [Google Scholar]
  46. Wenger C. R., Beardslee S., Owens M. A., Pounds G., Oldaker T., Vendely P., Pandian M. R., Harrington D., Clark G. M., McGuire W. L. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat. 1993 Oct;28(1):9–20. doi: 10.1007/BF00666351. [DOI] [PubMed] [Google Scholar]
  47. van Landeghem A. A., Poortman J., Nabuurs M., Thijssen J. H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 1985 Jun;45(6):2900–2906. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES